Download PDF
Thromb Haemost 1997; 78(04): 1215-1220
DOI: 10.1055/s-0038-1657717
Rapid Communication
Schattauer GmbH Stuttgart

Inhibition of Thrombin Generation in Plasma by Inhibitors of Factor Xa

D Prasa
1   The Zentrum für Vaskuläre Biologie und Medizin, Klinikum der Friedrich-Schiller-Universität Jena, Germany
,
L Svendsen
2   The Pentapharm Ltd., Basel, Switzerland
,
J Stürzebecher
1   The Zentrum für Vaskuläre Biologie und Medizin, Klinikum der Friedrich-Schiller-Universität Jena, Germany
› Author Affiliations
Further Information

Publication History

Received 31 1996

Accepted after resubmission 26 June 1997

Publication Date:
12 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

A series of inhibitors of factor Xa (FXa) were investigated using the thrombin generation assay to evaluate the potency and specificity needed to efficiently block thrombin generation in activated human plasma. By inhibiting FXa the generation of thrombin in plasma is delayed and decreased. Inhibitor concentrations which cause 50 percent inhibition of thrombin generation (IC50) correlate in principle with the Ki values for inhibition of free FXa. Recombinant tick anticoagulant peptide (r-TAP) is able to inhibit thrombin generation with considerably low IC50 values of 49 nM and 37 nM for extrinsic and intrinsic activation, respectively. However, the potent synthetic, low molecular weight inhibitors of FXa (Ki values of about 20 nM) are less effective in inhibiting the generation of thrombin with IC50 values at micromolar concentrations.

The overall effect of inhibitors of FXa in the thrombin generation assay was compared to that of thrombin inhibitors. On the basis of similar Ki values for the inhibition of the respective enzyme, synthetic FXa inhibitors are less effective than thrombin inhibitors. In contrast, the highly potent FXa inhibitor r-TAP causes a stronger reduction of the thrombin activity in plasma than the most potent thrombin inhibitor hirudin.

 

  • References

  • 1 Tuszynski GP, Gasic TB, Gasic GJ. Isolation and characterization of antistasin. An inhibitor of metastasis and coagulation. J Biol Chem 1987; 262: 9718-9723
    PubMedGoogle Scholar
  • 2 Waxman L, Smith DE, Arcuri KE, Vlasuk GP. Tick anticoagulant peptide (TAP) is a novel inhibitor of blood coagulation factor Xa. Science 1990; 248: 593-596
    CrossrefPubMedGoogle Scholar
  • 3 Neeper MP, Waxman L, Smith DE, Schulman CA, Sardana M, Ellis RW, Schaffer LW, Sieg PKS, Vlasuk GP. Characterization of recombinant tick anticoagulant peptide. A highly selective inhibitor of blood coagulation factor Xa. J Biol Chem 1990; 265: 17746-17752
    PubMedGoogle Scholar
  • 4 Jordan SP, Waxman L, Smith DE, Vlasuk GP. anticoagulant peptide: kinetic analysis of the recombinant inhibitor with blood coagulation factor Xa. Biochemistry 1990; 29: 11095-11100
    CrossrefPubMedGoogle Scholar
  • 5 Vlasuk GP. Structural and functional characterization of tick anticoagulant peptide (TAP): a potent and selective inhibitor of blood coagulation factor Xa. Thromb Haemost 1993; 70: 212-216
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Vlasuk GP, Ramjit D, Fujita T, Dunwiddie CT, Nutt EM, Smith DE, Shebuski RJ. Comparison of the in vivo anticoagulant properties of standard heparin and the highly selective factor Xa inhibitors antistasin and tick anticoagulant peptide (TAP) in a rabbit model of venous thrombosis. Thromb Haemost 1991; 65: 257-262
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Schaffer LW, Davidson JT, Vlasuk GP, Siegl PKS. Antithrombotic efficacy of recombinant tick anticoagulant peptide: a potent inhibitor of coagulation factor X in a primate model of arterial thrombosis. Circulation 1991; 84: 1741-1748
    CrossrefPubMedGoogle Scholar
  • 8 Sitko GR, Ramjit DR, Stabilito II, Lehman D, Lynch JJ, Vlasuk GP. Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor Xa inhibitor, tick anticoagulant peptide: Comparison to hirudin and heparin in a canine model of acute coronary artery thrombosis. Circulation 1992; 85: 805-815
    CrossrefPubMedGoogle Scholar
  • 9 Stürzebecher J, Stürzebecher U, Vieweg H, Wagner G, Hauptmann J, Markwardt F. Synthetic inhibitors of bovine factor Xa and thrombin – comparison of their anticoagulant efficiency. Thromb Res 1989; 54: 245-252
    CrossrefPubMedGoogle Scholar
  • 10 Tidwell RR, Webster WP, Shaver SR, Geratz P. Strategies for anticoagulation with synthetic protease inhibitors. Xa inhibitors versus thrombin inhibitors. Thromb Res 1980; 19: 339-349
    CrossrefPubMedGoogle Scholar
  • 11 Hara T, Yokoyama A, Ishihara H, Yokoyama Y, Nagahara T, Iwamoto M. DX-9065a, a new synthetic, potent anticoagulant and selective inhibitor for factor Xa. Thromb Haemost 1994; 71: 314-319
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Yamaguchi H, Yamada K, Kanetani N, Yokoyama Y. 1993 Patent P 05078344
    PubMed
  • 13 Stürzebecher J, Stürzebecher U. Are factor Xa inhibitors superior to thrombin inhibitors in anticoagulation?. Folia Haematol, Leipzig 1988; 115: 152-156
    PubMedGoogle Scholar
  • 14 Hauptmann J, Kaiser B, Nowak G, Stürzebecher J, Markwardt F. Comparison of the anticoagulant and antithrombotic effects of synthetic thrombin and factor Xa inhibitors. Thromb Haemost 1990; 63: 220-223
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Hauptmann J, Kaiser B. Anticoagulant potential of synthetic and recombinant inhibitors of factor Xa and thrombin in vitro. Blood Coag Fibrinol 1993; 4: 577-582
    CrossrefPubMedGoogle Scholar
  • 16 Hemker HC, Wielders S, Kessels H, Béguin S. Continuous registration of thrombin generation in plasma, its use for the determination of the thrombin potential. Thromb Haemost 1993; 70: 617-624
    Article in Thieme ConnectPubMedGoogle Scholar
  • 17 Prasa D, Svendsen L, Stürzebecher J. The ability of thrombin inhibitors to reduce the thrombin activity generated in plasma on extrinsic and intrinsic activation. Thromb Haemost 1997; 77: 498-503
    Article in Thieme ConnectPubMedGoogle Scholar
  • 18 Walsmann P. Über die Reinigung von Thrombinpräparaten. Pharmazie 1968; 23: 401-402
    PubMedGoogle Scholar
  • 19 Vieweg H, Wagner G. Synthese von Nα-(Arylsulfonylglycyl)-3-amidi-nophenylalaninestem als aktive und relativ spezifische Inhibitoren von Faktor Xa. Pharmazie 1987; 42: 267
    PubMedGoogle Scholar
  • 20 Stürzebecher J, Hauptmann J, Prasa D, Wikström P, Vieweg H. Synthesis and structure-activity relationships of potent thrombin inhibitors derived from piperazides of 3-amidinophenylalanine. J Med Chem. 1997. in press
    Google Scholar
  • 21 Dixon M. The determination of enzyme inhibitor constants. Biochem J 1953; 55: 170-171
    CrossrefPubMedGoogle Scholar
  • 22 Hemker HC, Béguin S. Thrombin generation in plasma: Its assessment via the endogenous thrombin potential. Thromb Haemost 1995; 74: 134-138
    Article in Thieme ConnectPubMedGoogle Scholar
  • 23 Stone SR, Hofsteenge J. Kinetics of the inhibition of thrombin by hirudin. Biochemistry 1986; 25: 4622-4628
    CrossrefPubMedGoogle Scholar
  • 24 Hilpert K, Ackermann J, Banner DW, Gast A, Gubemator K, Schmid G, Tschopp TB, van de WaterbeemdH. The development of potent and highly selective thrombin inhibitors. Eur J Med Chem 1995; 30 Suppl: S132-S138
    PubMedGoogle Scholar
  • 25 Béguin S, Lindhout T, Hemker HC. The mode of action of heparin in plasma. Thromb Haemost 1988; 60: 457-462
    Article in Thieme ConnectPubMedGoogle Scholar
  • 26 Lindhout T, Blezer R, Hemker HC. The anticoagulant mechanism of action of recombinant hirudin (CGP 39393) in plasma. Thromb Haemost 1990; 64: 464-468
    Article in Thieme ConnectPubMedGoogle Scholar
  • 27 Hemker HC, Béguin S. Mode of action of heparin and related drugs. Semin Thromb Hemost 1991; Suppl (Suppl. 01) 29-34
    PubMedGoogle Scholar
  • 28 Béguin S, Wielders S, Lormeau J-C, Hemker HC. The mode of action of CY216 and CY222 in plasma. Thromb Haemost 1992; 67: 33-41
    Article in Thieme ConnectPubMedGoogle Scholar
  • 29 Lormeau J-C, Herault P. Comparative inhibition of extrinsic and intrinsic thrombin generation by standard heparin, low molecular weight heparin and the synthetic AT III-binding pentasaccharide. Thromb Haemost 1993; 69: 152-6
    Article in Thieme ConnectPubMedGoogle Scholar
  • 30 Kessels H, Béguin S, Andree H, Hemker HC. Measurement of thrombin generation in whole blood – the effect of heparin and aspirin. Thromb Haemost 1994; 72: 78-83
    Article in Thieme ConnectPubMedGoogle Scholar
  • 31 Verhallen PFJ, Gehrmann G, Prasa D, Stürzebecher J. Measurement of thrombin generation in human plasma by two different methods (subsample/continuous): characterization of different anticoagulants. Thromb Haemost 1995; 73: 1247
    PubMedGoogle Scholar
  • 32 Gast A, Tschopp TB. Inhibition of extrinsic and intrinsic thrombin generation by a novel synthetic thrombin inhibitor (Ro 46-6240), recombinant hirudin and heparin in human plasma. Blood Coag Fibrinol 1995; 6: 553-560
    CrossrefPubMedGoogle Scholar
  • 33 Hauptmann J, Markwardt F, Walsmann P. Synthetic inhibitors of serine proteinases XVI. Influence of 3-and 4-amidinobenzyl derivatives on the formation and action of thrombin. Thromb Res 1978; 12: 735-744
    CrossrefPubMedGoogle Scholar
  • 34 Yokoyama T, Kelly AB, Marzec UM, Hanson SR, Kunitada S, Harker LA. Antithrombotic effects of orally active synthetic antagonist of activated factor X in nonhuman primates. Circulation 1995; 92: 485-491
    CrossrefPubMedGoogle Scholar
  • 35 Herbert JM, Bemat A, Dol F, Herault JP, Crepon B, Lormeau JC. DX 9065a, a novel, synthetic, selective and orally active inhibitor of factor Xa: In vitro and in vivo studies. J Pharmacol Exp Ther 1996; 276: 1030-1038
    PubMedGoogle Scholar
  • 36 Lynch Jr JJ, Sitko GR, Mellot MJ, Nutt EM, Lehinas ED, Friedman PA, Dunwiddie CT, Vlasuk GP. Maintenance of canine coronary artery patency following thrombolysis with front-loaded plus low dose maintenance conjunctive therapy: a comparison of factor Xa versus thrombin inhibition. J Cardiovasc Res 1994; 28: 78-85
    CrossrefPubMedGoogle Scholar
  • 37 Pieters J, Lindhout T. The limited importance of factor Xa inhibition to the anticoagulant property of heparin in thromboplastin-activated plasma. Blood 1988; 72: 2048-2052
    PubMedGoogle Scholar
  • 38 Krishnaswamy S, Vlasuk GP, Bergum PW. Assembly of the prothrombinase complex enhances the inhibition of bovine factor Xa by tick anticoagulant peptide. Biochemistry 1994; 33: 7897-7907
    CrossrefPubMedGoogle Scholar